Inspire Investing LLC boosted its position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 7.8% in the ...

Avior Wealth Management LLC decreased its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 7.0% during the 4th quarter, according to its most recent 13F filing with the ...

We recently published a list of 10 Stocks That Analysts Are Talking About. In this article, we are going to take a look at ...

Cytokinetics, Inc. (CYTK) stock saw a modest uptick, ending the day at $50.75 which represents a slight increase of $2.89 or 6.04% from the prior close of $47.86. The stock opened at $47.75 and ...

Stifel initiated coverage on Cytokinetics Incorporated (NASDAQ:CYTK), noting the company’s catalyst rich one to two years.

Stifel has initiated coverage of Cytokinetics (CYTK) with a buy rating, citing its drug aficamten, valuation and upcoming ...

Fintel reports that on January 22, 2025, Stifel initiated coverage of Cytokinetics (NasdaqGS:CYTK) with a Buy recommendation.

Canaccord Genuity analyst Caitlin Burrows initiated coverage on Orthofix Medical Inc. OFIX with a Buy rating and announced a ...

Cytokinetics, Inc. (CYTK), a biopharmaceutical company focused on muscle biology, on Monday announced the launch of the AMBER-HFpEF ...

Stifel analysts initiated coverage on Cytokinetics shares (NASDAQ:CYTK), assigning a Buy rating and setting a price target of ...

Stifel initiated coverage of Cytokinetics (CYTK) with a Buy rating and $80 price target Cytokinetics “is an out-of-favor stock” following the ...

Cytokinetics is on track to submit a New Drug Application (NDA) for aficamten in obstructive HCM (oHCM) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2024. This timeline ...